Skip to main content

Table 2 Menopausal hormone therapy and risk of ductal, lobular and tubular cancer

From: Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study

  Controls Ductal cancer Lobular cancer Tubular cancer
  No. No. ORa (95%CI) No. ORa (95%CI) No. ORa (95%CI)
Regimen        
No use 1,707 903 1.0 (Ref) 121 1.0 (Ref) 37 1.0 (Ref)
Medium potency estrogen alone        
   Non-exclusive use        
Ever 167 154 1.9 (1.5–2.4) 29 2.5 (1.6–3.9) 12 3.5 (1.8–6.9)
Current 72 67 2.0 (1.4–2.8) 10 2.1 (1.0–4.3) 1 0.7 (0.1–5.6)
   Exclusive useb        
Ever 76 73 2.0 (1.5–2.9) 12 2.4 (1.3–4.6) 1 0.7 (0.1–5.1)
   Duration        
<5 years 50 40 1.6 (1.0–2.5) 6 1.7 (0.7–4.2) 0 -
≥5 years 22 27 2.9 (1.6–5.2) 4 3.1 (1.0–9.5) 1 2.7 (0.3–21.2)
   Recency        
Current 31 26 1.6 (1.0–2.8) 6 3.0 (1.2–7.5) 0 -
Past 41 41 2.2 (1.4–3.5) 4 1.5 (0.5–4.2) 1 1.3 (0.2–10.3)
Medium potency estrogen-progestin        
   Non-exclusive use        
Ever 350 320 1.6 (1.3–1.9) 79 3.2c (2.3–4.4) 32 4.1c (2.4–7.0)
Current 222 208 1.7 (1.3–2.1) 43 2.8c (1.8–4.2) 16 3.3 (1.7–6.4)
   Exclusive useb        
Ever 232 215 1.6 (1.3–2.0) 43 2.7c (1.8–4.0) 16 3.2 (1.6–6.1)
   Duration        
<5 years 160 137 1.4 (1.1–1.8) 22 1.8 (1.1–3.1) 7 1.9 (0.8–4.7)
≥5 years 62 71 2.3 (1.6–3.3) 21 5.6c (3.2–9.7) 9 6.5c (2.8–14.9)
   Recency        
Current 155 171 2.0 (1.5–2.5) 36 3.3c (2.1–5.3) 14 4.2c (2.1–8.8)
Past 67 37 1.0 (0.7–1.5) 7 1.6 (0.7–3.6) 2 1.4 (0.3–6.1)
Sequential medium potency estrogen-progestind        
   Non-exclusive use        
Ever 186 199 1.9 (1.5–2.4) 46 3.6c (2.4–5.4) 19 4.5c (2.4–8.3)
Current 88 90 1.8 (1.3–2.4) 12 2.1 (1.1–4.0) 6 2.7 (1.1–7.1)
   Exclusive useb        
Ever 77 79 1.8 (1.3–2.5) 11 2.1 (1.0–4.2) 5 2.6 (0.9–7.4)
   Duration        
<5 years 56 63 1.9 (1.3–2.8) 7 1.7 (0.8–4.1) 4 2.8 (0.9–9.0)
≥5 years 15 16 2.1 (1.0–4.3) 3 3.4 (0.9–12.1) 1 2.7 (0.3–21.7)
   Recency        
Current 33 57 2.9 (1.8–4.6) 7 2.9 (1.2–7.1) 4 4.6 (1.4–15.8)
Past 38 22 1.1 (0.6–1.8) 3 1.3 (0.4–4.2) 1 1.2 (0.2–9.0)
Continuous medium potency estrogen-progestine        
   Non-exclusive use        
Ever 207 198 1.8 (1.4–2.2) 53 3.7c (2.5–5.4) 20 4.8c (2.6–8.9)
Current 124 92 1.4 (1.0–1.8) 25 2.9c (1.8–4.8) 6 2.3 (0.9–6.0)
   Exclusive useb        
Ever 114 85 1.4 (1.0–1.9) 22 2.8c (1.6–4.7) 6 2.6 (1.0–6.7)
   Duration        
<5 years 86 48 1.0 (0.7–1.4) 13 2.0c (1.0–3.8) 2 1.2 (0.3–5.2)
≥5 years 24 30 2.7 (1.5–4.7) 8 5.9 (2.5–14.0) 4 8.2 (2.4–27.5)
   Recency        
Current 90 68 1.4 (1.0–2.0) 18 2.9c (1.6–5.2) 6 3.3 (1.3–8.8)
Past 20 10 0.8 (0.4–1.8) 3 2.0 (0.6–6.9) 0 -
Low potency oral estrogen        
   Non-exclusive use        
Ever 314 192 1.2 (1.0–1.5) 42 1.9c (1.3–2.8) 9 1.4 (0.7–3.0)
Current 190 113 1.2 (0.9–1.6) 27 2.0c (1.3–3.2) 4 1.0 (0.3–2.9)
   Exclusive useb        
Ever 192 113 1.2 (0.9–1.5) 27 2.0c (1.3–3.2) 4 1.0 (0.3–2.8)
   Duration        
<5 years 139 87 1.3 (0.9–1.7) 23 2.3c (1.4–3.8) 3 1.0 (0.3–3.4)
≥5 years 50 25 1.1 (0.6–1.8) 4 1.2 (0.4–3.4) 1 1.0 (0.1–7.7)
   Recency        
Current 137 72 1.1 (0.8–1.5) 13 1.4 (0.7–2.5) 2 0.7 (0.2–3.1)
Past 52 40 1.6 (1.0–2.4) 14 3.8c (2.0–7.1) 2 1.6 (0.4–6.9)
Local estrogen        
   Non-exclusive use        
Ever 349 226 1.3 (1.0–1.5) 31 1.3 (0.8–1.9) 10 1.3 (0.7–2.8)
Current 229 130 1.1 (0.9–1.4) 13 0.8 (0.4–1.5) 7 1.5 (0.7–3.5)
   Exclusive useb        
Ever 236 133 1.1 (0.9–1.4) 14 0.8 (0.5–1.5) 7 1.5 (0.6–3.4)
   Duration        
<5 years 165 90 1.0 (0.8–1.3) 11 0.9 (0.5–1.8) 5 1.5 (0.6–4.0)
≥5 years 62 39 1.3 (0.8–1.9) 2 0.5 (0.1–1.9) 2 1.6 (0.4–7.0)
   Recency        
Current 168 94 1.1 (0.8–1.4) 10 0.9 (0.4–1.7) 6 1.8 (0.8–4.5)
Past 59 35 1.1 (0.7–1.7) 3 0.7 (0.2–2.2) 1 0.7 (0.1–5.6)
  1. Women with unknown age at menopause were excluded. Recency: Current = last use within 6 months before reference date (see methods for definition or reference date); Past = last use > 6 months before reference date. aAdjusted for age, age at first birth, age at menopause and recent body mass index (one year before data collection). bUsers of more than one kind of menopausal hormone therapy excluded. cStatistically significant difference compared with the estimate for ductal cancer. dSequential estrogen-progestin: progestin included <16 days per 28 days. eContinuous estrogen-progestin: progestin included > 19 days per 28 days. CI, confidence interval; OR, odds ratio; Ref, reference category.